Deramciclane (EGIS-3886) is used for the treatment of a number of anxiety disorders. Deramciclane differs from other anti anxiety medications in that it is not a benzodiazepine and so has a different structure and target. It antagonizes 5-HT2A receptors, agonizes 5-HT2C receptors, and functions as a GABA reuptake inhibitor.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Deramciclane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Deramciclane. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Deramciclane. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Deramciclane. |
| Hydrocodone | Deramciclane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Deramciclane. |
| Magnesium sulfate | The therapeutic efficacy of Deramciclane can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Deramciclane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Deramciclane may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Deramciclane. |
| Mirtazapine | Deramciclane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Deramciclane. |
| Orphenadrine | Deramciclane may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Deramciclane may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Deramciclane. |
| Pramipexole | Deramciclane may increase the sedative activities of Pramipexole. |
| Ropinirole | Deramciclane may increase the sedative activities of Ropinirole. |
| Rotigotine | Deramciclane may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Deramciclane. |
| Sodium oxybate | Deramciclane may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Deramciclane may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Deramciclane. |
| Thalidomide | Deramciclane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Deramciclane may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Yohimbine | The therapeutic efficacy of Deramciclane can be increased when used in combination with Yohimbine. |
| Mefloquine | The therapeutic efficacy of Deramciclane can be decreased when used in combination with Mefloquine. |
| Mianserin | The therapeutic efficacy of Deramciclane can be decreased when used in combination with Mianserin. |
| Orlistat | Orlistat can cause a decrease in the absorption of Deramciclane resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Topotecan | Deramciclane may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Deramciclane. |
| Atomoxetine | The metabolism of Atomoxetine can be decreased when combined with Deramciclane. |
| Dicoumarol | The risk or severity of adverse effects can be increased when Deramciclane is combined with Dicoumarol. |
| Phenindione | The risk or severity of adverse effects can be increased when Deramciclane is combined with Phenindione. |
| Warfarin | The risk or severity of adverse effects can be increased when Deramciclane is combined with Warfarin. |
| Phenprocoumon | The risk or severity of adverse effects can be increased when Deramciclane is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of adverse effects can be increased when Deramciclane is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of adverse effects can be increased when Deramciclane is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of adverse effects can be increased when Deramciclane is combined with Coumarin. |
| (R)-warfarin | The risk or severity of adverse effects can be increased when Deramciclane is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of adverse effects can be increased when Deramciclane is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of adverse effects can be increased when Deramciclane is combined with Fluindione. |
| Clorindione | The risk or severity of adverse effects can be increased when Deramciclane is combined with Clorindione. |
| Diphenadione | The risk or severity of adverse effects can be increased when Deramciclane is combined with Diphenadione. |
| Tioclomarol | The risk or severity of adverse effects can be increased when Deramciclane is combined with Tioclomarol. |
| (S)-Warfarin | The risk or severity of adverse effects can be increased when Deramciclane is combined with (S)-Warfarin. |
| Tetracosactide | The risk or severity of liver damage can be increased when Tetracosactide is combined with Deramciclane. |
| Ethanol | Deramciclane may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Deramciclane may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Deramciclane. |
| Zimelidine | The risk or severity of adverse effects can be increased when Deramciclane is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Deramciclane is combined with Dapoxetine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Deramciclane is combined with Seproxetine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Deramciclane is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Deramciclane is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Deramciclane is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Deramciclane is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Deramciclane is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Deramciclane is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Deramciclane is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Deramciclane is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Deramciclane is combined with Escitalopram. |
| Milnacipran | The risk or severity of adverse effects can be increased when Deramciclane is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Deramciclane is combined with Desvenlafaxine. |
| Levomilnacipran | The risk or severity of adverse effects can be increased when Deramciclane is combined with Levomilnacipran. |
| Indalpine | The risk or severity of adverse effects can be increased when Deramciclane is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Deramciclane is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Deramciclane is combined with Alaproclate. |
| Benzatropine | The metabolism of Benzatropine can be decreased when combined with Deramciclane. |
| Terfenadine | The metabolism of Terfenadine can be decreased when combined with Deramciclane. |
| Darifenacin | The metabolism of Darifenacin can be decreased when combined with Deramciclane. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Deramciclane is combined with Cocaine. |
| Quinidine | The therapeutic efficacy of Deramciclane can be decreased when used in combination with Quinidine. |
| Tolterodine | The metabolism of Tolterodine can be decreased when combined with Deramciclane. |
| Tiotropium | The metabolism of Tiotropium can be decreased when combined with Deramciclane. |
| Solifenacin | The metabolism of Solifenacin can be decreased when combined with Deramciclane. |
| Fesoterodine | The metabolism of Fesoterodine can be decreased when combined with Deramciclane. |
| Umeclidinium | The metabolism of Umeclidinium can be decreased when combined with Deramciclane. |
| Revefenacin | The metabolism of Revefenacin can be decreased when combined with Deramciclane. |
| Doxepin | The risk or severity of CNS depression can be increased when Doxepin is combined with Deramciclane. |
| Zopiclone | The risk or severity of adverse effects can be increased when Deramciclane is combined with Zopiclone. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Deramciclane. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Deramciclane. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of Deramciclane. |
| Ethchlorvynol | The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Deramciclane. |
| Succinylcholine | The risk or severity of CNS depression can be increased when Succinylcholine is combined with Deramciclane. |
| Eletriptan | The risk or severity of CNS depression can be increased when Eletriptan is combined with Deramciclane. |
| Enflurane | The risk or severity of CNS depression can be increased when Enflurane is combined with Deramciclane. |
| Butabarbital | The risk or severity of CNS depression can be increased when Butabarbital is combined with Deramciclane. |
| Butalbital | The risk or severity of CNS depression can be increased when Butalbital is combined with Deramciclane. |
| Methysergide | The risk or severity of CNS depression can be increased when Methysergide is combined with Deramciclane. |
| Cabergoline | The risk or severity of CNS depression can be increased when Cabergoline is combined with Deramciclane. |
| Phenytoin | The risk or severity of CNS depression can be increased when Phenytoin is combined with Deramciclane. |
| Topiramate | The risk or severity of CNS depression can be increased when Topiramate is combined with Deramciclane. |
| Clemastine | The risk or severity of CNS depression can be increased when Clemastine is combined with Deramciclane. |
| Etomidate | The risk or severity of CNS depression can be increased when Etomidate is combined with Deramciclane. |
| Morphine | The risk or severity of CNS depression can be increased when Morphine is combined with Deramciclane. |
| Talbutal | The risk or severity of CNS depression can be increased when Talbutal is combined with Deramciclane. |
| Pentobarbital | The risk or severity of CNS depression can be increased when Pentobarbital is combined with Deramciclane. |
| Zolmitriptan | The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Deramciclane. |
| Codeine | The risk or severity of CNS depression can be increased when Codeine is combined with Deramciclane. |